Posted by Michael Wonder on 28 Oct 2021
EMA nod for excessive daytime sleepiness med Ozawade
28 October 2021 - The EMA has approved Bioprojet’s Ozawade (pitolisant) for the treatment of excessive daytime sleepiness associated with obstructive sleep apnoea in adults.
Ozawade was evaluated in two Phase 3 clinical trials in the treatment of excessive daytime sleepiness in patients suffering from obstructive sleep apnoea – HAROSA I and HAROSA II.
